Page last updated: 2024-09-03

gefitinib and pyrazines

gefitinib has been researched along with pyrazines in 26 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(pyrazines)
Trials
(pyrazines)
Recent Studies (post-2010) (pyrazines)
5,2315662,91912,1651,3735,747

Research

Studies (26)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's14 (53.85)29.6817
2010's9 (34.62)24.3611
2020's3 (11.54)2.80

Authors

AuthorsStudies
Daud, A; Munster, P; Spriggs, DR1
Goldman, B1
Shiotsu, Y1
Capriotti, T1
Kaplow, R1
Masuda, N; Yanase, N; Yokoba, M1
Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H1
Auberger, J; Hilbe, W; Loeffler-Ragg, J; Wurzer, W1
Caldara, A; Graiff, C; Mandarà, M; Pedersini, R; Sava, T; Vattemi, E1
Berrino, L; Cascone, T; Ciardiello, F; Heymach, JV; Kim, WY; Lee, HY; Morelli, MP; Morgillo, F; Pepe, S; Rodolico, G; Tortora, G1
Kimpe, M; Nuyts, S; Prenen, H1
Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP1
Adachii, M; Ando, K; Hirose, T; Hosaka, T; Inoue, F; Ishida, H; Kadofuku, T; Kanome, T; Kusumoto, S; Ohmori, T; Ohnishi, T; Okuda, K; Saijo, N; Shirai, T; Sugiyama, T; Yamaoka, T1
Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; De Vita, F; Martinelli, E; Morgillo, F; Orditura, M; Troiani, T1
Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES1
Curtit, E; Mansi, L; Viel, E; Vignot, S1
Cassidy, J; Hochster, H1
Chen, CH; Chen, JY; Chen, WS; Chen, YJ; Chien, PH; Hsia, TC; Huang, WC; Liu, SH; Shih, CY; Tu, CY; Wei, YL; Yeh, MH; Yu, MC; Yu, YL1
Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O1
Cui, A; Hou, J; Hua, H; Jiang, Y; Luo, T; Song, P1
Chung, SJ; Kim, MS; Lee, JH; Maeng, HJ; Noh, CK1
Horn, L; Jie, F; Kelly, RJ; Krivoshik, A; Shepherd, FA1
Clevers, H; Joosten, SPJ; Mizutani, T; Pals, ST; Spaargaren, M1
Abdelgawad, MA; Al-Sanea, MM; Alharbi, KS; Eldehna, WM; Elsayed, ZM; Gomaa, HAM; Gotina, L; Grace Thomas Parambi, D; Mathew, B; Mohamed, MF; Youssif, BGM1
Ahmed, GF; Chang, JH; Chen, GY; Egile, C; Fang, J; Frigault, MM; Hartmaier, R; He, JX; Huang, JA; Li, W; Liu, XQ; Mellemgaard, A; Morgan, S; Shu, YQ; Verheijen, RB; Wu, YL; Yang, JJ; Yang, L; Yang, N; Zhou, C1
Cai, T; Du, W; Fu, Y; Huang, JA; Lei, Z; Liu, T; Liu, Z; Wang, A; Zeng, Y; Zhang, Y; Zhu, J1

Reviews

11 review(s) available for gefitinib and pyrazines

ArticleYear
New drugs in gynecologic cancer.
    Current treatment options in oncology, 2001, Volume: 2, Issue:2

    Topics: Aminopyridines; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cisplatin; Female; Gefitinib; Genital Neoplasms, Female; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Organoplatinum Compounds; Paclitaxel; Protein-Tyrosine Kinases; Pyrazines; Quinazolines; Trastuzumab

2001
[Current screening for molecular target therapy of cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib

2003
New oncology strategy: molecular targeting of cancer cells.
    Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses, 2004, Volume: 13, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cetuximab; Cysteine Endopeptidases; ErbB Receptors; Gefitinib; Genetics, Medical; Humans; Medical Oncology; Molecular Biology; Multienzyme Complexes; Neoplasms; Neovascularization, Pathologic; Nurse's Role; Oncology Nursing; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Quinazolines; Trastuzumab; Vascular Endothelial Growth Factor A

2004
Innovations in antineoplastic therapy.
    The Nursing clinics of North America, 2005, Volume: 40, Issue:1

    Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate

2005
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:6

    Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine

2005
Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
    Current cancer drug targets, 2006, Volume: 6, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neovascularization, Pathologic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A

2006
Systemic therapies for recurrent and/or metastatic salivary gland cancers.
    Expert review of anticancer therapy, 2008, Volume: 8, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Boronic Acids; Bortezomib; Cetuximab; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Trastuzumab

2008
Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets.
    Current opinion in oncology, 2008, Volume: 20, Issue:3

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Signal Transduction; Vascular Endothelial Growth Factor A

2008
Novel molecular targeted therapies for refractory thyroid cancer.
    Head & neck, 2012, Volume: 34, Issue:5

    Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat

2012
[EGFR/HER1: a target life].
    Bulletin du cancer, 2012, Feb-01, Volume: 99, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Cetuximab; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasm Proteins; Neoplasms; Panitumumab; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; Quinazolines; ras Proteins

2012
New oxaliplatin-based combinations in the treatment of colorectal cancer.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2003, Volume: 5 Suppl 3

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Quinazolines; Thiophenes

2003

Trials

2 trial(s) available for gefitinib and pyrazines

ArticleYear
A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 07-01, Volume: 30, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Survival Rate

2019
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
    Investigational new drugs, 2021, Volume: 39, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Triazines

2021

Other Studies

13 other study(ies) available for gefitinib and pyrazines

ArticleYear
Combinations of targeted therapies take aim at multiple pathways.
    Journal of the National Cancer Institute, 2003, Nov-19, Volume: 95, Issue:22

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Boronic Acids; Bortezomib; Clinical Trials as Topic; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Research Design

2003
[Molecular-targeted therapy for hormone-refractory prostate cancer].
    Hinyokika kiyo. Acta urologica Japonica, 2006, Volume: 52, Issue:6

    Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D

2006
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
    Journal of cellular physiology, 2008, Volume: 216, Issue:3

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Piperidines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Signal Transduction

2008
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
    Journal of experimental therapeutics & oncology, 2008, Volume: 7, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Carboplatin; Carmustine; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; Glial Fibrillary Acidic Protein; Glioblastoma; Immunohistochemistry; Indicators and Reagents; Mice; Proteasome Inhibitors; Pyrazines; Quinazolines; Rats; Temozolomide; Tetrazolium Salts; Thiazoles

2008
Combination effect between bortezomib and tumor necrosis factor alpha on gefitinib-resistant non-small cell lung cancer cell lines.
    Anticancer research, 2009, Volume: 29, Issue:6

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Pyrazines; Quinazolines; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha

2009
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.
    Lung cancer (Amsterdam, Netherlands), 2011, Volume: 71, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays

2011
Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.
    Breast cancer research : BCR, 2013, Nov-12, Volume: 15, Issue:6

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; I-kappa B Kinase; Lapatinib; Mice, SCID; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2013
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
    Acta pharmaceutica Hungarica, 2013, Volume: 83, Issue:4

    Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines

2013
Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Molecular medicine reports, 2015, Volume: 11, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Reactive Oxygen Species; Signal Transduction; src-Family Kinases

2015
Simultaneous quantification of volitinib and gefitinib in rat plasma by HPLC-MS/MS for application to a pharmacokinetic study in rats.
    Journal of separation science, 2017, Volume: 40, Issue:19

    Topics: Animals; Chromatography, High Pressure Liquid; Gefitinib; Pyrazines; Quinazolines; Rats; Tandem Mass Spectrometry; Triazines

2017
MET Signaling Overcomes Epidermal Growth Factor Receptor Inhibition in Normal and Colorectal Cancer Stem Cells Causing Drug Resistance.
    Gastroenterology, 2019, Volume: 157, Issue:4

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, APC; Humans; Intestinal Mucosa; Mutation; Neoplastic Stem Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Signal Transduction; Triazines

2019
Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety.
    Drug design, development and therapy, 2020, Volume: 14

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Gefitinib; Histone Deacetylase 1; Histone Deacetylase 2; Histone Deacetylase Inhibitors; HT29 Cells; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Pyrazines; Structure-Activity Relationship

2020
Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer.
    Journal of hematology & oncology, 2020, 12-07, Volume: 13, Issue:1

    Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Focal Adhesion Kinase 1; Gefitinib; Humans; Integrin alphaVbeta3; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Osteopontin; Protein Kinase Inhibitors; Pyrazines; Signal Transduction; Sulfonamides

2020